Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Phase II Study of Gemcitabine and Erlotinib As Adjuvant Therapy In Patients With Resected Pancreatic Cancer

This study has been terminated.
(Study published November 2010 and no further work will be done)
Sponsor:
Collaborator:
Genentech, Inc.
Information provided by (Responsible Party):
University of Pittsburgh
ClinicalTrials.gov Identifier:
NCT00336700
First received: June 12, 2006
Last updated: January 16, 2013
Last verified: January 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: November 2011
  Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)